Immuno-oncology

2019 Q3 Outlook Webinar

16 Jun 2022

Informa Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019. 

Gilead Says 16 Cancer Centers Getting Ready To Administer Yescarta

By Joseph Haas 31 Oct 2017

Within weeks of its acquisition of Kite, Gilead is working to launch its first immuno-oncology drug, with a goal of training.

Immuno-Oncology Overview

By Colin White, Robert Jeng & Jolene Lau 19 Sep 2017

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well

PD-1/PD-L1 Inhibitors: The First Wave of Immuno-Oncology

By Dustin Phan 18 Sep 2017

Recently, Informa Pharma Intelligence conduced an insightful webinar regarding the current market landscape and outlook for immuno-oncology.

BMS' Opdivo Approval In CRC Overshadowed By Keytruda Dominance

03 Aug 2017

The US FDA has approved BMS' Opdivo for previously treated patients with some forms of colorectal cancer, however direct competition from Merck's Keytruda may limit its success.

PD-1 Data Emerges In Cervical Cancer

By Lucie Ellis 27 Jul 2017

Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.

Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer

25 Jul 2017

As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.

Boehringer Ingelheim's Partnering Focus: An Interview With Ioannis Sapountzis

05 Jul 2017

Trying to catch up with peers in both immuno-oncology and NASH, the German pharma has assigned Sapountzis to lead its US business development efforts.

Pink Sheet

Immuno-oncology Drugs And The Trouble With Market Access

By Francesca Bruce 07 Jun 2017

The clinical potential of immuno-oncology drugs does not seem to be reflected in approaches by health technology assessment bodies, with different interpretations of data.